Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00441818 | Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 59 | TanoxINDUSTRY | 1 | May 9, 2008 | clinicaltrials |
| VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates |
| completed |
| Phase 2 |
| 35 |
| Korean Multiple Myeloma Working PartyOTHER |
| 1 |
| May 6, 2008 |
| clinicaltrials |
| NCT00349115 | TCD Followed by autoSCT for Newly Diagnosed MM Patients | unknown | Phase 2 | 43 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00250861 | Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma | terminated | Phase 2 | 110 | US Oncology ResearchINDUSTRY | 1 | Apr 21, 2008 | clinicaltrials |
| NCT00129168 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 100 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00233909 | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 55 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00302861 | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) | terminated | Phase 1 / Phase 2 | 86 | Genitope CorporationINDUSTRY | 0 | Mar 18, 2008 | clinicaltrials |
| NCT00510471 | Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma | terminated | Phase 2 | — | Genitope CorporationINDUSTRY | 1 | Mar 18, 2008 | clinicaltrials |
| NCT00001237 | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001430 | A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001567 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001839 | A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome | completed | Phase 2 | 182 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00066092 | Pegfilgrastim PBPC Mobilization Study | completed | Phase 2 | 41 | AmgenINDUSTRY | 0 | Feb 28, 2008 | clinicaltrials |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 152 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 2 | 66 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00265928 | Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 46 | University of VirginiaOTHER | 1 | Jan 28, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00141700 | Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 10, 2008 | clinicaltrials |
| NCT00044902 | Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) | completed | Phase 2 | — | AmgenINDUSTRY | 0 | Dec 28, 2007 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00116467 | Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia | completed | Phase 2 | 55 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00580450 | Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies | unknown | Phase 1 / Phase 2 | 9 | University Of PerugiaOTHER | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00271063 | Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia | unknown | Phase 1 / Phase 2 | 34 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00041990 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 17, 2007 | clinicaltrials |
| NCT00367497 | Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | terminated | Phase 2 | 5 | Keio UniversityOTHER | 1 | Nov 20, 2007 | clinicaltrials |
| NCT00561301 | Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma | unknown | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Nov 20, 2007 | clinicaltrials |
| NCT00120198 | Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients | terminated | Phase 2 | 50 | Geriatric Oncology ConsortiumOTHER | 1 | Nov 16, 2007 | clinicaltrials |
| NCT00558220 | R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas(R-MCEB) | completed | Phase 2 | 106 | Czech Lymphoma Study GroupOTHER | 1 | Nov 14, 2007 | clinicaltrials |
| NCT00457288 | Efficacy and Safety of TF002 in Cutaneous Mastocytosis | completed | Phase 2 | 30 | JADO Technologies GmbHINDUSTRY | 1 | Nov 12, 2007 | clinicaltrials |
| NCT00556127 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma(DLBCL) | completed | Phase 2 | 94 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Nov 9, 2007 | clinicaltrials |
| NCT00057447 | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 24 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00536393 | Treatment of Disseminated High Grade Lymphoma | completed | Phase 2 / Phase 3 | 100 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00199186 | Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | unknown | Phase 2 | — | Johann Wolfgang Goethe University HospitalOTHER | 1 | Oct 19, 2007 | clinicaltrials |
| NCT00129155 | MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Oct 4, 2007 | clinicaltrials |
| NCT00529880 | Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | unknown | Phase 2 | 19 | Cooperative Study Group A for HematologyNETWORK | 1 | Sep 27, 2007 | clinicaltrials |
| NCT00062894 | Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab | completed | Phase 1 / Phase 2 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Sep 17, 2007 | clinicaltrials |
| NCT00517712 | Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia(IAPLSG04) | unknown | Phase 2 / Phase 3 | 400 | Christian Medical College, Vellore, IndiaOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00061672 | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | completed | Phase 2 | 67 | AbbottINDUSTRY | 1 | Aug 15, 2007 | clinicaltrials |
| NCT00514969 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase(CML003) | completed | Phase 2 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00510926 | Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 80 | University of BolognaOTHER | 1 | Aug 3, 2007 | clinicaltrials |
| NCT00511121 | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) | terminated | Phase 2 | 5 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00511303 | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | completed | Phase 2 | 200 | University of BolognaOTHER | 0 | Aug 3, 2007 | clinicaltrials |
| NCT00169130 | ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma | completed | Phase 2 / Phase 3 | 300 | Lymphoma Study AssociationOTHER | 2 | Jul 13, 2007 | clinicaltrials |
| NCT00491127 | Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 10 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2008source: clinicaltrials